Key result
Perinatally-acquired HIV is not associated with diffuse myocardial fibrosis compared to uninfected controls.
Why the study?
Cardiovascular disease is a leading cause of death in people living with HIV and myocardial fibrosis is well-described in adult-acquired HIV, but the burden of fibrosis in perinatally acquired HIV needed evaluation.
Is perinatally acquired HIV infection associated with increased diffuse myocardial fibrosis compared to uninfected controls?
Case-Control (n=40)
No
Is perinatally acquired HIV infection associated with increased diffuse myocardial fibrosis compared to uninfected controls?
Absolute Event Rate: 25.5% vs 27.5%
p-value: p=0.24
Perinatally-acquired HIV in patients on long-term antiretroviral therapy is not associated with increased diffuse myocardial fibrosis on CMR, suggesting early ART may be cardioprotective.
May indicate fibrosis burden in perinatal HIV; leaves open need for CMR screening or targeted interventions.
Background: Cardiovascular disease (CVD) remains a leading cause of death in people living with HIV. Myocardial fibrosis is well-described in HIV infection acquired in adulthood. We evaluate the burden of fibrosis by cardiac magnetic resonance in people with perinatal HIV infection. Methods: Individuals with perinatally acquired HIV (pnHIV) diagnosed before 10 years-old and on antiretroviral treatment for ≥ 6 months were matched with uninfected controls. Patients with significant cardiometabolic co-morbidities and pregnancy were excluded. Diffuse fibrosis was assessed by cardiac magnetic resonance (CMR). with native T1 mapping for calculation of extracellular volume fraction (ECV). Viability was assessed with late gadolinium enhancement. The normality of fibrosis was assessed using the Komogrov-Smirnov test. Fibrosis between the groups was analyzed using a Mann-Whitney U test, as the data was not normally distributed. Statistical significance was defined as a p-valve < 0.05. Results: Fourteen adults with pnHIV group and 26 controls (71% female and 86% Black race) were assessed. The average (± standard deviation) age in the study group was 29 (± 4.3) years-old. All pnHIV had been on ART for decades. Demographic data, CMR functional/volumetric data, and pre-contrast T1 mapping values were similar between groups. Diastolic function was normal in 50% of pnHIV patients and indeterminate in most of the remainder (42%). There was no statistically significant difference in ECV between groups; p = 0.24. Conclusion: Perinatally-acquired HIV was not associated with diffuse myocardial fibrosis. Early exposure to ART may be cardioprotective against development of myocardial fibrosis in patients with perinatal HIV.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2023) conducted a case-control in Perinatally acquired HIV (n=40). Perinatally acquired HIV vs. Uninfected historic controls was evaluated on Extracellular volume (ECV) fraction (p=0.24). Perinatally-acquired HIV was not associated with diffuse myocardial fibrosis, with no significant difference in extracellular volume fraction compared to uninfected controls (25.5% vs 27.5%, p=0.24).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: